VASTHERA Co. Ltd.

[Not Yet Scheduled]
Vasthera was founded on February 1st, 2018 as a start-up venture company that develops innovative synthetic drugs treating various arterial diseases. Our goal is to cure the patients suffering from pulmonary arterial hypertension (PAH), in-stent restenosis, angina, and atherosclerosis. To target various arterial diseases, we build the pipelines, including small molecules, proteins, and oligonucleotides. We have been optimizing the lead compounds and discovered many candidate compounds for primarily targeting pulmonary arterial hypertension, a rare arterial disease. The R&D power is based on the strong scientific achievement on redox-dependent receptor signaling in vascular cells [Nature, 2005; Molecular Cell, 2011; Circulation, 2013]. In particular, we found that the 2-Cys peroxiredoxin (Prdx) enzymes, which is a new type of thiol peroxidase that regulates receptor signaling, are inactivated in the arterial lesions with PAH and atherosclerosis.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
VTC-04PH
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
VASTHERA Co. Ltd.